Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max S Topp

Showing results (91-100 of 122) with videos related to

Pageof 13
Sort By:
Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyMaria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.
British Journal of Haematology|September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphomaMax S Topp, Tom van Meerten, Roch Houot, et al.
Hemasphere|December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapyLukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
The Lancet. Oncology|December 20, 2014
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S Topp, Nicola Gökbuget, Anthony S Stein, et al.
Blood|October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Leukemia|March 25, 2026
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myelomaJohannes Waldschmidt, David Fandrei, Judith S Hecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Nature Medicine|February 23, 2021
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myelomaMatteo C Da Vià, Oliver Dietrich, Marietta Truger, et al.
Pageof 13

Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
Blood|August 14, 2020
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphomaPier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2016
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I StudyMaria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot, et al.
British Journal of Haematology|September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphomaMax S Topp, Tom van Meerten, Roch Houot, et al.
Hemasphere|December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapyLukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
The Lancet. Oncology|December 20, 2014
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S Topp, Nicola Gökbuget, Anthony S Stein, et al.
Blood|October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.
Leukemia|March 25, 2026
Flare of clonal hematopoiesis, TP53 expansion and prior melphalan drive post-CAR-T myeloid disorders in multiple myelomaJohannes Waldschmidt, David Fandrei, Judith S Hecker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Nature Medicine|February 23, 2021
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myelomaMatteo C Da Vià, Oliver Dietrich, Marietta Truger, et al.
Pageof 13